Drug intelligence / Profile preview

oNKo-046

Development stage: Preclinical
Lead developer: Audax Bio
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

oNKo-046 is an investigational cell therapy candidate being developed for cancer treatment. It is a CAR-NK (chimeric antigen receptor-natural killer) cell therapy, designed to enhance the anti-tumor function and fitness of NK cells, particularly under repetitive antigen stimulation and immunosuppressive conditions. The drug targets intracellular checkpoints in orthogonal cytokine pathways; when paired with another candidate (oNKo-038), it leads to improved CAR-NK cell function. The primary indication for oNKo-046 is neoplasms (cancers). As of March 2025, its highest development phase is preclinical. The developer and active organization behind this drug is oNKo-innate Pty Ltd.[1][2][4]

Beyond the preview

Go deeper on oNKo-046.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on oNKo-046.

Explore the full profile